UY34301A - COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit - Google Patents
COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-KitInfo
- Publication number
- UY34301A UY34301A UY34301A UY34301A UY34301A UY 34301 A UY34301 A UY 34301A UY 34301 A UY34301 A UY 34301A UY 34301 A UY34301 A UY 34301A UY 34301 A UY34301 A UY 34301A
- Authority
- UY
- Uruguay
- Prior art keywords
- quinase
- inhibitors
- kit
- compositions
- compounds
- Prior art date
Links
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 title 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 241000950314 Figura Species 0.000 abstract 1
- FWYUJENICVGSJH-UHFFFAOYSA-M sodium;2-[bis[2-[2-(2-methyl-5-nitroimidazol-1-yl)ethoxy]-2-oxoethyl]amino]acetate Chemical compound [Na+].CC1=NC=C([N+]([O-])=O)N1CCOC(=O)CN(CC([O-])=O)CC(=O)OCCN1C([N+]([O-])=O)=CN=C1C FWYUJENICVGSJH-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530038P | 2011-09-01 | 2011-09-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY34301A true UY34301A (es) | 2013-04-05 |
Family
ID=46829904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY34301A UY34301A (es) | 2011-09-01 | 2012-08-29 | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8569283B2 (enExample) |
| EP (1) | EP2751104B1 (enExample) |
| JP (1) | JP6134319B2 (enExample) |
| KR (1) | KR101962495B1 (enExample) |
| CN (1) | CN103797011B (enExample) |
| AP (1) | AP2014007493A0 (enExample) |
| AR (1) | AR087753A1 (enExample) |
| AU (1) | AU2012302042B2 (enExample) |
| BR (1) | BR112014004560A2 (enExample) |
| CA (1) | CA2845169C (enExample) |
| CL (1) | CL2014000492A1 (enExample) |
| CO (1) | CO6900141A2 (enExample) |
| CR (1) | CR20140107A (enExample) |
| CU (1) | CU20140024A7 (enExample) |
| EA (1) | EA026152B1 (enExample) |
| ES (1) | ES2761332T3 (enExample) |
| GT (1) | GT201400034A (enExample) |
| IL (1) | IL231227A0 (enExample) |
| MA (1) | MA35460B1 (enExample) |
| MX (1) | MX339937B (enExample) |
| PE (1) | PE20140909A1 (enExample) |
| PH (1) | PH12014500372A1 (enExample) |
| PL (1) | PL2751104T3 (enExample) |
| PT (1) | PT2751104T (enExample) |
| SG (1) | SG2014014369A (enExample) |
| TN (1) | TN2014000068A1 (enExample) |
| TW (1) | TW201313717A (enExample) |
| UY (1) | UY34301A (enExample) |
| WO (1) | WO2013033167A1 (enExample) |
| ZA (1) | ZA201401175B (enExample) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9199981B2 (en) * | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| AP2014007493A0 (en) | 2011-09-01 | 2014-03-31 | Irm Llc | Compounds and compositions as C-KIT kinase inhibitors |
| CN109568319A (zh) | 2013-01-10 | 2019-04-05 | 普尔莫凯恩股份有限公司 | 非选择性激酶抑制剂 |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| WO2015054574A1 (en) | 2013-10-11 | 2015-04-16 | Zisman Lawrence S | Spray dry formulations |
| US20150288928A1 (en) * | 2014-04-08 | 2015-10-08 | Sony Corporation | Security camera system use of object location tracking data |
| CN105384738B (zh) * | 2014-08-21 | 2017-08-29 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
| KR102710552B1 (ko) | 2015-07-02 | 2024-09-25 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 항균 화합물 |
| US10474987B2 (en) * | 2015-08-05 | 2019-11-12 | Whirlpool Corporation | Object recognition system for an appliance and method for managing household inventory of consumables |
| US20190256509A1 (en) * | 2016-06-08 | 2019-08-22 | Chrysalis, Inc. | Histone demethylase inhibitors |
| EP3472152A1 (en) | 2016-06-16 | 2019-04-24 | Janssen Sciences Ireland Unlimited Company | Heterocyclic compounds as antibacte rials |
| BR112018076126A2 (pt) | 2016-06-16 | 2019-03-26 | Janssen Sciences Ireland Unlimited Company | compostos heterocíclicos como antibacterianos |
| EP3515446B1 (en) | 2016-09-19 | 2023-12-20 | Novartis AG | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
| EP3532063A4 (en) | 2016-10-27 | 2020-07-22 | Pulmokine, Inc. | POLYTHERAPY FOR THE TREATMENT OF PULMONARY HYPERTENSION |
| US20180162291A1 (en) * | 2016-12-12 | 2018-06-14 | Wipro Limited | System and method of dynamically adjusting field of view of an image capturing device |
| KR20240053077A (ko) | 2017-03-01 | 2024-04-23 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 병용 요법 |
| WO2018203219A1 (en) | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| KR102625224B1 (ko) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | 피라졸-온 유도체를 유효성분으로 포함하는 자가면역질환의 예방, 개선 또는 치료용 조성물 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| AU2020274564A1 (en) * | 2019-05-13 | 2021-12-09 | Novartis Ag | Crystalline forms of N- (5- (5- ( (1R, 2S) -2-fluorocyclopropyl) -1, 2, 4-oxadiazol-3-yl) -2-methylphenyl) imidazo [1, 2-a] pyridine-3-carboxamide |
| US12187703B2 (en) | 2019-05-13 | 2025-01-07 | Novartis Ag | Crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as Raf inhibitors for the treatment of cancer |
| WO2021035788A1 (zh) | 2019-08-29 | 2021-03-04 | 中国科学院合肥物质科学研究院 | 吡唑衍生物及其用途 |
| ES2978573T3 (es) | 2019-09-13 | 2024-09-16 | Janssen Sciences Ireland Unlimited Co | Compuestos antibacterianos |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| BR112022011017A2 (pt) | 2019-12-13 | 2022-08-16 | Nippon Shinyaku Co Ltd | Composto que funciona como inibidor de receptor quinase de pdgf, e composição |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4181921A4 (en) | 2020-07-15 | 2025-02-26 | Third Harmonic Bio, Inc. | CRYSTALLINE FORMS OF A SELECTIVE C-KIT KINASE INHIBITOR |
| TW202237097A (zh) | 2020-11-19 | 2022-10-01 | 美商第三諧波生物公司 | 選擇性ｃ－ｋｉｔ激酶抑制劑之醫藥組合物及其製造及使用方法 |
| EP4308239A1 (en) | 2021-03-16 | 2024-01-24 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CA3212074A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| WO2022194905A1 (en) | 2021-03-17 | 2022-09-22 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| IL312366A (en) | 2021-10-28 | 2024-06-01 | Janssen Sciences Ireland Unlimited Co | Imidazopyridine amides and related compounds for use in the treatment of bacterial infections |
| WO2024089170A1 (en) | 2022-10-27 | 2024-05-02 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| EP4626884A1 (en) * | 2022-11-30 | 2025-10-08 | Blueprint Medicines Corporation | N-phenyl-pyrazolo[1,5-a]pyridine-3-carboxamide derivatives as wild type c-kit kinase inhibitors for the treatment of urticaria |
| AU2023390239A1 (en) * | 2022-12-07 | 2025-07-24 | Third Harmonic Bio, Inc. | Compounds and compositions as c-kit kinase inhibitors |
| JP2025541191A (ja) * | 2022-12-07 | 2025-12-18 | サード ハーモニック バイオ， インコーポレイテッド | Ｃ－ｋｉｔキナーゼ阻害剤としての化合物及び組成物 |
| WO2024223859A1 (en) | 2023-04-26 | 2024-10-31 | Janssen Pharmaceutica Nv | Antibacterial compounds |
| WO2025072330A1 (en) * | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| WO2025256552A1 (zh) * | 2024-06-11 | 2025-12-18 | 上海翰森生物医药科技有限公司 | 吡唑类衍生物抑制剂、其制备方法和应用 |
| WO2025256609A1 (en) * | 2024-06-13 | 2025-12-18 | Third Harmonic Bio, Inc. | Crystalline forms of a selective c-kit kinase inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| WO2004001903A2 (en) | 2002-06-20 | 2003-12-31 | Beacon Looms, Inc. | Knitted electrical conductor fabric |
| CA2591321C (en) | 2004-09-09 | 2013-09-24 | Natco Pharma Limited | Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase |
| EP2942349A1 (en) | 2004-12-23 | 2015-11-11 | Deciphera Pharmaceuticals, LLC | Enzyme modulators and treatments |
| US7754717B2 (en) | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
| JP2010509349A (ja) * | 2006-11-03 | 2010-03-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
| JP6117104B2 (ja) * | 2010-11-15 | 2017-04-19 | アッヴィ・インコーポレイテッド | Ｎａｍｐｔおよびｒｏｃｋ阻害薬 |
| US20130023751A1 (en) | 2011-07-18 | 2013-01-24 | Samuel Victor Lichtenstein | Water retention monitoring |
| WO2013033203A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as c-kit kinase inhibitors |
| WO2013033620A1 (en) | 2011-09-01 | 2013-03-07 | Irm Llc | Compounds and compositions as pdgfr kinase inhibitors |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| AP2014007493A0 (en) | 2011-09-01 | 2014-03-31 | Irm Llc | Compounds and compositions as C-KIT kinase inhibitors |
-
2012
- 2012-08-29 AP AP2014007493A patent/AP2014007493A0/xx unknown
- 2012-08-29 SG SG2014014369A patent/SG2014014369A/en unknown
- 2012-08-29 PE PE2014000295A patent/PE20140909A1/es not_active Application Discontinuation
- 2012-08-29 EA EA201490545A patent/EA026152B1/ru not_active IP Right Cessation
- 2012-08-29 EP EP12756885.5A patent/EP2751104B1/en active Active
- 2012-08-29 CA CA2845169A patent/CA2845169C/en active Active
- 2012-08-29 PL PL12756885T patent/PL2751104T3/pl unknown
- 2012-08-29 CN CN201280042743.4A patent/CN103797011B/zh active Active
- 2012-08-29 PT PT127568855T patent/PT2751104T/pt unknown
- 2012-08-29 JP JP2014528537A patent/JP6134319B2/ja active Active
- 2012-08-29 AU AU2012302042A patent/AU2012302042B2/en not_active Ceased
- 2012-08-29 ES ES12756885T patent/ES2761332T3/es active Active
- 2012-08-29 PH PH1/2014/500372A patent/PH12014500372A1/en unknown
- 2012-08-29 WO PCT/US2012/052802 patent/WO2013033167A1/en not_active Ceased
- 2012-08-29 KR KR1020147008107A patent/KR101962495B1/ko active Active
- 2012-08-29 MX MX2014002484A patent/MX339937B/es active IP Right Grant
- 2012-08-29 UY UY34301A patent/UY34301A/es not_active Application Discontinuation
- 2012-08-29 BR BR112014004560A patent/BR112014004560A2/pt not_active Application Discontinuation
- 2012-08-29 US US13/598,213 patent/US8569283B2/en active Active
- 2012-08-31 TW TW101131942A patent/TW201313717A/zh unknown
- 2012-08-31 AR ARP120103223 patent/AR087753A1/es unknown
-
2013
- 2013-09-19 US US14/031,792 patent/US8754071B2/en active Active
-
2014
- 2014-02-17 TN TNP2014000068A patent/TN2014000068A1/en unknown
- 2014-02-17 ZA ZA2014/01175A patent/ZA201401175B/en unknown
- 2014-02-27 GT GT201400034A patent/GT201400034A/es unknown
- 2014-02-27 CL CL2014000492A patent/CL2014000492A1/es unknown
- 2014-02-27 IL IL231227A patent/IL231227A0/en unknown
- 2014-02-27 CU CU20140024A patent/CU20140024A7/es unknown
- 2014-02-28 CO CO14043417A patent/CO6900141A2/es unknown
- 2014-02-28 CR CR20140107A patent/CR20140107A/es unknown
- 2014-03-28 MA MA36864A patent/MA35460B1/fr unknown
- 2014-04-22 US US14/258,963 patent/US9023839B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY34301A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
| UY34300A (es) | COMPUESTOS Y COMPOSICIONES COMO INHIBIDORES DE LA QUINASA c-Kit | |
| UY34092A (es) | Nuevos compuestos como inhibidores de jak | |
| UY34051A (es) | Derivados de pirrolotriazinona como inhibidores de pi3k | |
| UY34472A (es) | Derivados modificados de 4-fenil-piridina | |
| UY34352A (es) | 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| UY34550A (es) | Bencilpirazoles sustituidos | |
| UY34763A (es) | Inhibidores de la agregación plaquetaria | |
| UY33958A (es) | Inhibidores de la glucosilceramida sintasa | |
| UY34393A (es) | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia | |
| UY34523A (es) | Derivados de betulina | |
| UY33929A (es) | Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas | |
| UY33925A (es) | Inhibidores tricíclicos de quinasas | |
| UY34445A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
| CR20120635A (es) | Compuestos heterocìclicos de nitrògeno ùtiles como inhibidores de pde10 | |
| UY34145A (es) | Compuestos inhibidores de metaloenzimas | |
| UY34146A (es) | Compuestos inhibidores de metaloenzimas | |
| UY34156A (es) | Compuestos inhibidores de metaloenzimas | |
| UY34004A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA | |
| CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| UY34536A (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos | |
| UY33930A (es) | Inhibidores novedosos de quinasas | |
| UY34648A (es) | Amidas como inhibidores de pim | |
| UY34027A (es) | Inhibidores sustituidos de acetil-coa carboxilasa. | |
| UY34374A (es) | Benzilindazoles sustituidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20201020 |